Baker Julian's Form 4 filing
TScan Therapeutics, Inc. (TCRX) · filed Apr 23, 2024
- Accession no.
- 0000950170-24-046916
- Filed
- Apr 23, 2024, 4:17 PM ET
- Trade date
- Apr 19, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Director |
| Baker FelixCIK 0001087940 | Director |
| Baker Bros. Advisors LPCIK 0001263508 | Director |
| Baker Brothers Life Sciences LPCIK 0001363364 | Director |
| 667, L.P.CIK 0001551139 | Director |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2024 | Common Stock | PPurchaseAcquired | +825,968 | $7.13 | +$5,889,069.24 | 4,018,678 | Indirect | |
| Apr 19, 2024 | Common Stock | PPurchaseAcquired | +8,851,451 | $7.13 | +$63,109,960.48 | 43,158,741 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.